Published in N Engl J Med on July 29, 2004
Screening for breast cancer. JAMA (2005) 4.56
Dedicated breast CT: initial clinical experience. Radiology (2008) 3.70
Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. J Am Coll Surg (2009) 2.79
Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol (2010) 2.77
Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol (2009) 2.74
Breast MRI: guidelines from the European Society of Breast Imaging. Eur Radiol (2008) 2.52
Imaging studies for the early detection of breast cancer. Dtsch Arztebl Int (2008) 2.19
Reasons women at elevated risk of breast cancer refuse breast MR imaging screening: ACRIN 6666. Radiology (2010) 2.13
International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer (2008) 2.13
Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol (2007) 1.78
Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts. Eur Radiol (2009) 1.76
Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science (2014) 1.74
Beyond mammography: new frontiers in breast cancer screening. Am J Med (2013) 1.61
Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res (2008) 1.59
The cost of breast cancer screening in the Medicare population. JAMA Intern Med (2013) 1.53
Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer. Mayo Clin Proc (2010) 1.51
Choice of management of southern Chinese BRCA mutation carriers. World J Surg (2010) 1.50
Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. Br J Cancer (2006) 1.48
Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer (2011) 1.41
Molecular breast imaging: use of a dual-head dedicated gamma camera to detect small breast tumors. AJR Am J Roentgenol (2008) 1.39
Outcomes of multimodality breast screening for women at increased risk of familial breast cancer. World J Surg (2010) 1.38
Improved diagnostic accuracy of breast MRI through combined apparent diffusion coefficients and dynamic contrast-enhanced kinetics. Magn Reson Med (2011) 1.36
Online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol (2012) 1.35
BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol (2010) 1.32
Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst (2009) 1.31
Breast cancer imaging: a perspective for the next decade. Med Phys (2008) 1.29
Physicians' experiences with BRCA1/2 testing in community settings. J Clin Oncol (2008) 1.29
American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol (2008) 1.29
Meta-analysis of quantitative diffusion-weighted MR imaging in the differential diagnosis of breast lesions. BMC Cancer (2010) 1.26
Compositional breast imaging using a dual-energy mammography protocol. Med Phys (2010) 1.26
Selection of diagnostic features on breast MRI to differentiate between malignant and benign lesions using computer-aided diagnosis: differences in lesions presenting as mass and non-mass-like enhancement. Eur Radiol (2009) 1.24
Identification of novel high-frequency DNA methylation changes in breast cancer. PLoS One (2007) 1.22
Breast cancer screening with MRI--what are the data for patients at high risk? N Engl J Med (2004) 1.17
Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dtsch Arztebl Int (2011) 1.17
Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer (2012) 1.15
Positron emission mammography in breast cancer presurgical planning: comparisons with magnetic resonance imaging. Eur J Nucl Med Mol Imaging (2010) 1.15
Development of a Bayesian classifier for breast cancer risk stratification: a feasibility study. Eplasty (2010) 1.14
Breast cancer detection: radiologists' performance using mammography with and without automated whole-breast ultrasound. Eur Radiol (2010) 1.12
The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat (2007) 1.10
Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence. Breast Cancer Res Treat (2009) 1.10
Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers. Radiology (2010) 1.09
Multimodality screening of high-risk women: a prospective cohort study. J Clin Oncol (2009) 1.09
Nonmalignant breast lesions: ADCs of benign and high-risk subtypes assessed as false-positive at dynamic enhanced MR imaging. Radiology (2012) 1.07
Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Res Treat (2010) 1.07
Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection? Eur Radiol (2006) 1.07
Generation of a suite of 3D computer-generated breast phantoms from a limited set of human subject data. Med Phys (2013) 1.07
Vacuum-assisted biopsies under MR guidance: results of 72 procedures. Eur Radiol (2010) 1.03
Breast cancer in the personal genomics era. Curr Genomics (2010) 1.02
Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience. BMC Cancer (2006) 1.01
Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population. BMC Health Serv Res (2009) 1.01
Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol (2012) 1.01
Imaging in breast cancer: magnetic resonance imaging. Breast Cancer Res (2005) 1.00
Frequency of malignancy seen in probably benign lesions at contrast-enhanced breast MR imaging: findings from ACRIN 6667. Radiology (2010) 1.00
Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol (2014) 0.98
Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting. Fam Cancer (2009) 0.97
Screening behavior in women at increased familial risk for breast cancer. Fam Cancer (2006) 0.97
Design study of a high-resolution breast-dedicated PET system built from cadmium zinc telluride detectors. Phys Med Biol (2010) 0.97
Evaluation of tumor-derived MRI-texture features for discrimination of molecular subtypes and prediction of 12-month survival status in glioblastoma. Med Phys (2015) 0.97
Contrast-enhanced magnetic resonance imaging of the breast: the value of pharmacokinetic parameters derived from fast dynamic imaging during initial enhancement in classifying lesions. Eur Radiol (2008) 0.96
Visualizing implanted tumors in mice with magnetic resonance imaging using magnetotactic bacteria. Clin Cancer Res (2009) 0.95
Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation. Open Med (2007) 0.95
Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis. Cancer (2011) 0.94
Real-time three-dimensional optical coherence tomography image-guided core-needle biopsy system. Biomed Opt Express (2012) 0.94
Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery. BMC Womens Health (2010) 0.94
Effects of age on the detection and management of breast cancer. Cancers (Basel) (2015) 0.94
Advanced diagnostic breast cancer imaging: variation and patterns of care in Washington state. J Oncol Pract (2013) 0.93
Preclinical MR fingerprinting (MRF) at 7 T: effective quantitative imaging for rodent disease models. NMR Biomed (2015) 0.93
Morphologic blooming in breast MRI as a characterization of margin for discriminating benign from malignant lesions. Acad Radiol (2006) 0.93
A short guide to hereditary diffuse gastric cancer. Hered Cancer Clin Pract (2007) 0.93
Unilateral and bilateral breast cancer in women surviving pediatric Hodgkin's disease. Int J Radiat Oncol Biol Phys (2008) 0.92
Intensified surveillance for early detection of breast cancer in high-risk patients. Breast Care (Basel) (2015) 0.92
Evaluation of the diagnostic power of thermography in breast cancer using Bayesian network classifiers. Comput Math Methods Med (2013) 0.92
Detection of non-palpable breast cancer in asymptomatic women by using unenhanced diffusion-weighted and T2-weighted MR imaging: comparison with mammography and dynamic contrast-enhanced MR imaging. Eur Radiol (2010) 0.91
Evaluation of breast involvement in relation to Cowden syndrome: a radiological and clinicopathological study of patients with PTEN germ-line mutations. Eur Radiol (2005) 0.91
A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 0.91
Exposure to low-dose radiation and the risk of breast cancer among women with a familial or genetic predisposition: a meta-analysis. Eur Radiol (2010) 0.91
MRI-guided needle localization of suspicious breast lesions: results of a freehand technique. Eur Radiol (2006) 0.91
Individually tailored screening of breast cancer with genes, tumour phenotypes, clinical attributes, and conventional risk factors. Br J Cancer (2013) 0.90
Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers. Cancer (2012) 0.90
Magnetic resonance imaging in breast cancer: A literature review and future perspectives. World J Clin Oncol (2014) 0.90
Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk. Br J Cancer (2014) 0.90
Magnetic resonance imaging in the evaluation of ductal carcinoma in situ. J Natl Cancer Inst Monogr (2010) 0.90
What hinders minority ethnic access to cancer genetics services and what may help? Eur J Hum Genet (2013) 0.90
Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers. Breast Cancer Res Treat (2011) 0.90
Should women 40 to 49 years of age be offered mammographic screening? Can Fam Physician (2006) 0.89
Expanding the indications for MRI in the diagnosis and treatment of breast cancer: what is best practice? J Med Radiat Sci (2015) 0.89
Breast MRI use uncommon among U.S. women. Cancer Epidemiol Biomarkers Prev (2012) 0.89
The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage. Br J Cancer (2009) 0.88
Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI. Eur Radiol (2008) 0.88
Looking different, feeling different: women's reactions to risk-reducing breast and ovarian surgery. Fam Cancer (2012) 0.88
Pearls and pitfalls in breast MRI. Br J Radiol (2011) 0.87
The added value of quantitative multi-voxel MR spectroscopy in breast magnetic resonance imaging. Eur Radiol (2011) 0.87
Comparison of breast tissue measurements using magnetic resonance imaging, digital mammography and a mathematical algorithm. Phys Med Biol (2012) 0.87
New insights into breast cancer genetics and impact on patient management. Curr Treat Options Oncol (2007) 0.86
Semiautomated multimodal breast image registration. Int J Biomed Imaging (2012) 0.86
Multimodality breast cancer screening in women with a familial or genetic predisposition. Curr Oncol (2010) 0.86
Stiffness of the surrounding tissue of breast lesions evaluated by ultrasound elastography. Eur Radiol (2014) 0.86
Multiparametric MR Imaging of Breast Cancer. Magn Reson Imaging Clin N Am (2016) 0.86
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 29.45
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin (2007) 12.19
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst (2003) 11.27
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol (2007) 8.65
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Quality-of-life effects of prostate-specific antigen screening. N Engl J Med (2012) 7.21
Management of lung nodules detected by volume CT scanning. N Engl J Med (2009) 6.79
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat Genet (2011) 5.70
Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med (2009) 5.36
Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res (2011) 4.84
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med (2009) 4.60
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res (2007) 4.41
Subtypes of breast cancer show preferential site of relapse. Cancer Res (2008) 4.38
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet (2003) 4.20
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol (2007) 4.19
Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst (2007) 3.55
Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial. Am J Respir Crit Care Med (2013) 3.47
Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer (2003) 3.47
Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med (2014) 3.46
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol (2007) 3.32
Genes associated with breast cancer metastatic to bone. J Clin Oncol (2006) 3.21
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med (2003) 3.15
Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A (2008) 3.08
Intraoperative ultrasound guidance for palpable breast cancer excision (COBALT trial): a multicentre, randomised controlled trial. Lancet Oncol (2012) 3.04
Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst (2009) 2.88
Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer (2007) 2.85
Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med (2013) 2.77
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat (2009) 2.76
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
Volumetric breast density estimation from full-field digital mammograms. IEEE Trans Med Imaging (2006) 2.63
Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer (2010) 2.62
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer (2012) 2.61
Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol (2006) 2.48
Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. Eur Urol (2013) 2.43
Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol (2005) 2.37
Sentinel-lymph-node procedure in colon and rectal cancer: a systematic review and meta-analysis. Lancet Oncol (2011) 2.36
A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer (2006) 2.35
Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imaging (2010) 2.32
Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000. J Natl Cancer Inst (2012) 2.30
Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol (2006) 2.28
What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev (2011) 2.25
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst (2002) 2.25
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res (2004) 2.17
Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. J Clin Oncol (2005) 2.14
Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest (2004) 2.05
EMT is the dominant program in human colon cancer. BMC Med Genomics (2011) 2.05
Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol (2010) 2.04
Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. Ann Intern Med (2012) 1.99
Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol (2007) 1.97
Ultrasonography and fine-needle aspiration cytology can spare breast cancer patients unnecessary sentinel lymph node biopsy. Ann Surg Oncol (2006) 1.95
Identification of chronic obstructive pulmonary disease in lung cancer screening computed tomographic scans. JAMA (2011) 1.94
Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer (2005) 1.93
Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States. Cancer Epidemiol Biomarkers Prev (2010) 1.93
Breast tomosynthesis in clinical practice: initial results. Eur Radiol (2009) 1.89
Mammography screening and risk of breast cancer death: a population-based case-control study. Cancer Epidemiol Biomarkers Prev (2011) 1.85
Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India. J Natl Cancer Inst (2008) 1.84
Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res Treat (2010) 1.83
Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam. J Natl Cancer Inst (2010) 1.83
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol (2007) 1.78
Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev (2011) 1.77
Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation. Blood (2011) 1.76
Patients' perceptions of the side-effects of prostate cancer treatment--a qualitative interview study. Soc Sci Med (2006) 1.76
Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer. BMC Cancer (2007) 1.75
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat (2010) 1.75
Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma. Cancer (2003) 1.74
Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol (2009) 1.74
Factors influencing the local failure rate of radiofrequency ablation of colorectal liver metastases. Ann Surg Oncol (2006) 1.72
Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women. Plast Reconstr Surg (2006) 1.70
Additional double reading of screening mammograms by radiologic technologists: impact on screening performance parameters. J Natl Cancer Inst (2007) 1.69
Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol (2003) 1.68
Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2003) 1.67
RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res (2003) 1.67
Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. J Pathol (2004) 1.67
Gleason score, age and screening: modeling dedifferentiation in prostate cancer. Int J Cancer (2006) 1.64
A cluster-randomized trial of screening for language delay in toddlers: effects on school performance and language development at age 8. Pediatrics (2007) 1.63
Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res (2008) 1.61
The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol (2007) 1.61
Ranking and rankability of hospital postoperative mortality rates in colorectal cancer surgery. Ann Surg (2014) 1.61
Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol (2011) 1.59